Beta Blockers and Calcium Channel Blockers

  • Alexandra-Maria Neagoe
  • Emrush Rexhaj
  • Ehud Grossman
  • Franz H. Messerli
Part of the Contemporary Cardiology book series (CONCARD)


Calcium channel blockers and beta blockers are medicines commonly prescribed for the treatment of hypertension and tachyarrhythmias. Beta blockers prevent stimulation of the beta-adrenergic receptors at the nerve endings of the sympathetic nervous system and therefore reduce systolic pressure, heart rate, and cardiac contractility and output. Calcium channel blockers block voltage-gated calcium channels and inhibit the influx of calcium ions into cardiac and smooth muscle cells. The decrease in intracellular calcium inhibits cardiac contraction, but promotes vasodilatation. Beta blockers are likely overprescribed; they are ineffective antihypertensive agents. Current evidence supports their use in patients with systolic heart failure and for rate control.


Beta blocker Calcium channel blocker Heart failure Hypertension Arrhythmia Hemodynamics 


Beta Blockers

  1. 1.
    James Black (pharmacologist). Wikipedia.Google Scholar
  2. 2.
    Poirier L, Tobe SW. Contemporary use of b-blockers: clinical relevance of subclassification. Can J Cardiol. 2014;30(5 Suppl):S9–S15.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Predel HG, et al. Integrated effects of the vasodilating beta-blocker nebivolol on exercise performance, energy metabolism, cardiovascular and neurohormonal parameters in physically active patients with arterial hypertension. J Hum Hypertens. 2001;15(10):715–21.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Polónia J, et al. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator properties or with angiotensin receptor blockers. Blood Press Monit. 2010;15(5):235–9.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Karabacak M, Doğan A, Tayyar Ş, Özaydın M, Erdoğan D. Carvedilol and nebivolol improve left ventricular systolic functions in patients with non-ischemic heart failure. Anatol J Cardiol. 2015;15(4):271–6.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Epstein SE, Braunwald E. Clinical and hemodynamic appraisal of beta adrenergic blocking drugs. Ann N Y Acad Sci. 1967;139(3):952–67.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Nakano A, Kusakari T. Effect of beta adrenergic blockade on the cardiovascular dynamics. Am J Phys. 1966;210(4):833–7.CrossRefGoogle Scholar
  8. 8.
    Takahashi H, et al. Effect of vasodilatory B-adrenoceptor blockers on cardiovascular haemodynamics in anaesthetized rats. Clin Exp Pharmacol Physiol. 2002;29:198–203.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Kamp O, Metra M, Bugatti S, Bettari L, Dei Cas A, Petrini N, Dei Cas L. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release. Drugs. 2010;70(1):41–56.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Messerli FH, Rimoldi SF, Bangalore S, Bavishi C, Laurent S. When an increase in central systolic pressure overrides the benefits of heart rate lowering. J Am Coll Cardiol. 2016;68(7):754–62.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Man In’t Veld AJ, Schalekamp MA. Effects of 10 different beta-adrenoceptor antagonists on hemodynamics, plasma renin activity, and plasma norepinephrine in hypertension: the key role of vascular resistance changes in relation to partial agonist activity. J Cardiovasc Pharmacol. 1983;5(1):S30–45.Google Scholar
  12. 12.
    Cruickshank JM. Beta blockers in clinical practice. 2nd ed. Edinburgh: Churchill-Livingstone; 1994. p. 1–1204.Google Scholar
  13. 13.
    Buhler FR, Laragh JH, Baer L, et al. Propranolol inhibition of renin secretion: a specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med. 1972;287(24):1209–14.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Castenfors J, Johnsson H, Oro L. Effect of alprenolol on blood pressure and plasma renin activity in hypertensive patients. Acta Med Scand. 1973;193(3):189–95.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Hansson L. Beta-adrenergic blockade in essential hypertension: effects of propranolol on hemodynamic parameters and plasma renin activity. Acta Med Scand Suppl. 1973;550:1–40.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Vincent HH, Man In’t Veld AJ, Boomsma F, et al. Elevated plasma noradrenaline in response to beta-adrenoceptor stimulation in man. Br J Clin Pharmacol. 1982;13(5):717–21.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol. 2008;52(18):1482.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998;279(23):1903–7.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Kuyper LM, Khan NA. Atenolol vs nonatenolol β-blockers for the treatment of hypertension: a meta-analysis. Can J Cardiol. 2014;30(5 Suppl):S47–53.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Messerli FH, Grossman E. Beta blockers in hypertension: is carvedilol different? Am J Cardiol. 2004;93(9A):7B–12B.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, Lip GY, Coats AJ, Andersson B, Kirchhof P, von Lueder TG, Wedel H, Rosano G, Shibata MC, Rigby A, Flather MD. Beta-blockers in heart failure collaborative group. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384:2235–43.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, ElAllaf D, Vı ´t J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Ja ´n A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P. MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and wellbeing in patients with heart failure: the MetoprololCR/XL randomized intervention trial in congestive heart failure (MERIT-HF). JAMA. 2000;283:1295–130.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–8.CrossRefGoogle Scholar
  24. 24.
    Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349–55.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Hjalmarson A, et al. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353:2001–7.Google Scholar
  26. 26.
    Packer M. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:2194–9.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    CIBIS-IIInvestigatorsandCommittees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13.CrossRefGoogle Scholar
  28. 28.
    Flather MD, Shibata MC, Coats AJS, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Bo¨hm M, Anker SD, Thompson SG, Poole-Wilson PA, SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215–25.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Hjalmarson A, et al. The beta blocker heart attack trial: beta blocker heart attack study group. JAMA. 1981;246(18):2073–4.Google Scholar
  30. 30.
    Pedersen TR. The Norwegian multicenter study of Timolol after myocardial infarction. Circulation. 1983;67(6/2):I49–53.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385–90.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339(8):489–97.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Bangalore S, Makani H, Radford M, Thakur K, Toklu B, Katz SD, DiNicolantonio JJ, Devereaux PJ, Alexander KP, Wetterslev J, Messerli FH. Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med. 2014;127(10):939–53.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, Ohman EM, Cannon CP, Smith SC, Zeymer U, Hoffman EB, Messerli FH, Bhatt DL, REACH Registry Investigators. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13):1340–9. Scholar
  35. 35.
    Messerli FH, Bangalore S, Yao SS, Steinberg JS. Cardioprotection with beta-blockers: myths, facts and Pascal’s wager. J Intern Med. 2009;266(3):232–41.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Messerli FH, Suter T, Bangalore S. What ever happened to cardioprotection with β-blockers? Mayo Clin Proc. 2018;93(4):401–3.PubMedCrossRefPubMedCentralGoogle Scholar


  1. 37.
    De Paoli P, Cerbai E, Koidl B, Kirchengast M, Sartiani L, Mugelli A. Selectivity of different calcium antagonists on T- and L-type calcium currents in guinea-pig ventricular myocytes. Pharmacol Res. 2002;46(6):491–7.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 38.
    Ruzicka M, Leenen FH. Relevance of 24 H blood pressure profile and sympathetic activity for outcome on short- versus long-acting 1,4-dihydropyridines. Am J Hypertens. 1996;9(1):86–94.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 39.
    Leenen FH. Clinical relevance of 24 h blood pressure control by 1,4-dihydropyridines. Am J Hypertens. 1996;9(10 Pt 2):97S–104S; discussion 8S–9S.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 40.
    Grossman E, Messerli FH. Calcium antagonists. Prog Cardiovasc Dis. 2004;47(1):34–57.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 41.
    Amodeo C, Kobrin I, Ventura HO, et al. Immediate and short-term hemodynamic effects of diltiazem in patients. With hypertension. Circulation. 1986;73:108–13.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 42.
    Grossman E, Oren S, Garavaglia GE, et al. Systemic and regional hemodynamic and humoral effects of nitrendipine in essential hypertension. Circulation. 1988;78:1394–400.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 43.
    Grossman E, Messerli FH, Oren S, et al. Cardiovascular effects of isradipine in essential hypertension. Am J Cardiol. 1991;68:65–70.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 44.
    Little WC, Cheng CP, Elvelin L, et al. Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine. Cardiovasc Drugs Ther. 1995;9:657–63.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 45.
    Schmieder RE, Messerli FH, Garavaglia GE, et al. Cardiovascular effects of verapamil in patients with essential hypertension. Circulation. 1987;75:1030–6.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 46.
    Ventura HO, Messerli FH, Oigman W, et al. Immediate hemodynamic effects of a new calcium-channel blocking agent (nitrendipine) in essential hypertension. Am J Cardiol. 1983;51:783–6.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 47.
    Szlachcic J, Tubau JF, Vollmer C, et al. Effect of diltiazem on left ventricular mass and diastolic filling in mild to moderate hypertension. Am J Cardiol. 1989;63:198–201.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 48.
    Muiesan G, Agabiti-Rosei E, Romanelli G, et al. Adrenergic activity and left ventricular function during treatment of essential hypertension with calcium antagonists. Am J Cardiol. 1986;57:44D–9D.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 49.
    Schulman SP, Weiss JL, Becker LC, et al. The effects of antihypertensive therapy on left ventricular mass in elderly patients. N Engl J Med. 1990;322:1350–6.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 50.
    Granier P, Douste-Blazy MY, Tredez P, et al. Improvement in left ventricular hypertrophy and left ventricular diastolic function following verapamil therapy in mild to moderate hypertension. Eur J Clin Pharmacol. 1990;39(Suppl 1):S45–6.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 51.
    Weiss RJ, Bent B. Diltiazem-induced left ventricular mass regression in hypertensive patients. J Clin Hypertens. 1987;3:135–43.PubMedPubMedCentralGoogle Scholar
  16. 52.
    Senda Y, Tohkai H, Kimura M, et al. ECG-gated cardiac scan and echocardiographic assessments of left ventricular hypertrophy: reversal by 6-month treatment with diltiazem. J Cardiovasc Pharmacol. 1990;16:298–304.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 53.
    Gottdiener JS, Reda DJ, Massie BM, et al. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on antihypertensive agents. Circulation. 1997;95:2007–14.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 54.
    van Leeuwen JT, Smit AJ, May JF, et al. Comparative effects of diltiazem and lisinopril on left ventricular structure and filling in mild-to-moderate hypertension. J Cardiovasc Pharmacol. 1995;26:983–9.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 55.
    Leenen FH, Fourney A. Comparison of the effects of amlodipine and diltiazem on 24-hour blood pressure, plasma catecholamines, and left ventricular mass. Am J Cardiol. 1996;78:203–7.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 56.
    Ferrara LA, de Simone G, Mancini M, et al. Changes in left ventricular mass during a double-blind study with chlorthalidone and slow-release nifedipine. Eur J Clin Pharmacol. 1984;27:525–8.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 57.
    Phillips RA, Ardeljan M, Shimabukuro S, et al. Effect of nifedipine GITS on left ventricular mass and diastolic function in severe hypertension. J Cardiovasc Pharmacol. 1991;17:S172–4.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 58.
    Totteri A, Scopelliti G, Campanella G, et al. [Evaluation of regression of left ventricular hypertrophy after antihypertensive therapy. Comparative echo-Doppler study of ace inhibitors and calcium antagonists]. Italian. Minerva Cardioangiol. 1993;41:231–7.PubMedPubMedCentralGoogle Scholar
  23. 59.
    Yamakado T, Teramura S, Oonishi T, et al. Regression of left ventricular hypertrophy with long-term treatment of nifedipine in systemic hypertension. Clin Cardiol. 1994;17:615–8.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 60.
    Kirpizidis HG, Papazachariou GS. Comparative effects of fosinopril and nifedipine on regression of left ventricular hypertrophy in hypertensive patients: a double-blind study. Cardiovasc Drugs Ther. 1995;9:141–3.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 61.
    Myers MG, Leenen FH, Tanner J. Differential effects of felodipine and nifedipine on 24-h blood pressure and left ventricular mass. Am J Hypertens. 1995;8:712–8.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 62.
    Ferrara LA, Fasano ML, de Simone G, et al. Antihypertensive and cardiovascular effects of nitrendipine: a controlled study vs. placebo. Clin Pharmacol Ther. 1985;38:434–8.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 63.
    Drayer JI, Hall WD, Smith VE, et al. Effect of the calcium channel blocker nitrendipine on left ventricular mass in patients with hypertension. Clin Pharmacol Ther. 1986;40:679–85.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 64.
    Giles TD, Sander GE, Roffidal LC, et al. Comparison of nitrendipine and hydrochlorothiazide for systemic hypertension. Am J Cardiol. 1987;60:103–6.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 65.
    Machnig T, Henneke KH, Engels G, et al. Nitrendipine vs. captopril in essential hypertension: effects on circadian blood pressure and left ventricular hypertrophy. Cardiology. 1994;85:101–10.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 66.
    Costantino G, Di Lorenzo L, Buonissimo S, et al. Echocardiographic analysis of anatomical and functional changes in the left heart ventricle during antihypertensive treatment with nicardipine. G Ital Cardiol. 1988;18:644–8.PubMedPubMedCentralGoogle Scholar
  31. 67.
    Gokce C, Oram A, Kes S, et al. Effects of nicardipine on left ventricular dimensions and hemodynamics in systemic hypertension. Am J Cardiol. 1990;65:680–2.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 68.
    Sumimoto T, Hiwada K, Ochi T, et al. Effects of long-term treatment with sustained-release nicardipine on left ventricular hypertrophy and function in patients with essential hypertension. J Clin Pharmacol. 1994;34:266–9.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 69.
    Langan J, Rodriguez-Manas L, Sareli P, et al. Clinical experience in hypertension. Cardiology. 1997;88(Suppl 1):56–62.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 70.
    Kloner RA, Sowers JR, DiBona GF, et al. Effect of amlodipine on left ventricular mass in the amlodipine cardiovascular community trial. J Cardiovasc Pharmacol. 1995;26:471–6.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 71.
    Bignotti M, Grandi AM, Gaudio G, et al. One-year antihypertensive treatment with amlodipine: effects on 24-hour blood pressure and left ventricular anatomy and function. Acta Cardiol. 1995;50:135–42.PubMedPubMedCentralGoogle Scholar
  36. 72.
    Skoularigis J, Strugo V, Weinberg J, et al. Effects of amlodipine on 24-hour ambulatory blood pressure profiles electrocardiographic monitoring, and left ventricular mass and function in black patients with very severe hypertension. J Clin Pharmacol. 1995;35:1052–9.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 73.
    Carr AA, Prisant LM. The new calcium antagonist isradipine. Effect on blood pressure and the left ventricle in black hypertensive patients. Am J Hypertens. 1990;3:8–15.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 74.
    Saragoca MA, Portela JE, Abreu P, et al. Regression of left ventricular hypertrophy in the short-term treatment of hypertension with isradipine. Am J Hypertens. 1991;4:188S–90S.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 75.
    Vyssoulis GP, Karpanou EA, Pitsavos CE, et al. Regression of left ventricular hypertrophy with isradipine antihypertensive therapy. Am J Hypertens. 1993;6:82S–5S.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 76.
    Manolis AJ, Kolovou G, Handanis S, et al. Regression of left ventricular hypertrophy with isradipine in previously untreated hypertensive patients. Am J Hypertens. 1993;6:86S–8S.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 77.
    Modena MG, Masciocco G, Rossi R, et al. Evaluation of the effectiveness of isradipine SRO in the treatment of hypertensive patients with left ventricular hypertrophy. Cardiovasc Drugs Ther. 1994;8:153–60.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 78.
    Galderisi M, Celentano A, Garofalo M, et al. Reduction of left ventricular mass by short-term antihypertensive treatment with isradipine: a double-blind comparison with enalapril. Int J Clin Pharmacol Ther. 1994;32:312–6.PubMedPubMedCentralGoogle Scholar
  43. 79.
    Grandi AM, Bignotti M, Gaudio G, et al. Ambulatory blood pressure and left ventricular changes during antihypertensive treatment: perindopril versus isradipine. J Cardiovasc Pharmacol. 1995;26:737–41.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 80.
    Pringle SD, Barbour M, Simpson IA. Effect of felodipine on left ventricular mass and Doppler-derived hemodynamics in patients with essential hypertension [abstract]. Proceedings of the 4th international symposium on calcium antagonists: pharmacology and clinical research, Florence, Italy, May 25–27, 1989.Google Scholar
  45. 81.
    Cerasola G, Cottone S, Nardi E, et al. Reversal of cardiac hypertrophy and left ventricular function with the calcium antagonist felodipine in hypertensive patients. J Hum Hypertens. 1990;4:703–8.PubMedPubMedCentralGoogle Scholar
  46. 82.
    Wetzchewald D, Klaus D, Garanin G, et al. Regression of left ventricular hypertrophy during long-term antihypertensive treatment – a comparison between felodipine and the combination of felodipine and metoprolol. J Intern Med. 1992;231:303–8.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 83.
    Leenen FH, Holliwell DL. Antihypertensive effect of felodipine associated with persistent sympathetic activation and minimal regression of left ventricular hypertrophy. Am J Cardiol. 1992;69:639–45.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 84.
    Nalbantgil I, Onder R, Killiccioglu B, et al. The efficacy of felodipine ER on regression of left ventricular hypertrophy in patients with primary hypertension. Blood Press. 1996;5:285–91.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 85.
    Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41–6.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 86.
    Kohlhardt M, Fleckenstein A. Inhibition of the slow inward current by nifedipine in mammalian ventricular myocardium. Naunyn Schmiedeberg’s Arch Pharmacol. 1977;298:267–72.CrossRefGoogle Scholar
  51. 87.
    Nayler WG, Szeto J. Effect of verapamil on contractility, oxygen utilization, and calcium exchangeability in mammalian heart muscle. Cardiovasc Res. 1972;6:120–8.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 88.
    Sung RJ, Elser B, McAllister RG. Intravenous verapamil for termination of re-entrant supraventricular tachycardias: intracardiac studies correlated with plasma verapamil concentrations. Ann Intern Med. 1980;93:682–9.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 89.
    Bonow RO, Rosing DR, Bacharach SL, et al. Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy. Circulation. 1981;64:787–96.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 90.
    Brooks N, Cattell M, Pidgeon J, et al. Unpredictable response to nifedipine in severe cardiac failure. Br Med J. 1980;281:1324.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 91.
    Chew CY, Hecht HS, Collett JT, et al. Influence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease. Am J Cardiol. 1981;47:917–22.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 92.
    de Buitleir M, Rowland E, Krikler DM. Hemodynamic effects of nifedipine given alone and in combination with atenolol in patients with impaired left ventricular function. Am J Cardiol. 1985;55:15E–20E.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 93.
    Elkayam U, Weber L, McKay C, et al. Spectrum of acute hemodynamic effects of nifedipine in severe congestive heart failure. Am J Cardiol. 1985;56:560–6.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 94.
    Ferlinz J, Easthope JL, Aronow WS. Effects of verapamil on myocardial performance in coronary disease. Circulation. 1979;59:313–9.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 95.
    Klein HO, Ninio R, Oren V, et al. The acute hemodynamic effects of intravenous verapamil in coronary artery disease. Assessment by equilibrium gated radionuclide ventriculography. Circulation. 1983;67:101–10.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 96.
    Lamping KA, Gross GJ. Differential effects of intravenous vs. intracoronary nifedipine on myocardial segment function in ischemic canine hearts. J Pharmacol Exp Ther. 1984;228:28–32.PubMedPubMedCentralGoogle Scholar
  61. 97.
    Serruys PW, Brower RW, ten Katen HJ, et al. Regional wall motion from radiopaque markers after intravenous and intracoronary injections of nifedipine. Circulation. 1981;63:584–91.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 98.
    Thomas P, Sheridan DJ. Vascular selectivity of felodipine: clinical experience. J Cardiovasc Pharmacol. 1990;15(Suppl 4):S17–20.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 99.
    Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective randomized amlodipine survival evaluation study group. N Engl J Med. 1996;335:1107–14.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 100.
    Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-heart failure trial (V-HeFT) study group. Circulation. 1997;96:856–63.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 101.
    Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ, Investigators CAMELOT. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292(18):2217–25.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 102.
    Bangalore S, Parkar S, Messerli FH. Long-acting calcium antagonists in patients with coronary artery disease: a meta-analysis. Am J Med. 2009;122(4):356–65.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 103.
    Wright JM, Musini VM, Gill R. First-line drugs for hypertension. Cochrane Database Syst Rev. 2018;4:CD001841.PubMedPubMedCentralGoogle Scholar
  68. 104.
    Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417–28.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 105.
    Bangalore S, Fakheri R, Toklu B, Messerli FH. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ. 2016;352:i438.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 106.
    Wang JG, Li Y, Franklin SS, Safar M. Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers: a quantitative overview. Hypertension. 2007;50(1):181–8.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 107.
    Hjalmarson A, et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288(23):2981–97.Google Scholar
  72. 108.
    Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 109.
    Opie LH. First line drugs in chronic stable effort angina – the case for newer, longer-acting calcium channel blocking agents. J Am Coll Cardiol. 2000;36(6):1967–71.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 110.
    Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The systolic hypertension in Europe (Syst-Eur) trial Investigators. Lancet. 1997;350(9080):757–64. Epub 1997/09/23. PubMed PMID: 9297994.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 111.
    Lund-Johansen P, Omvik P. Central hemodynamic changes of calcium antagonists at rest and during exercise in essential hypertension. J Cardiovasc Pharmacol. 1987;10(Suppl 1):S139–48.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 112.
    Rinkenberger RL, Prystowsky EN, Heger JJ, Troup PJ, Jackman WM, Zipes DP. Effects of intravenous and chronic oral verapamil administration in patients with supraventricular tachyarrhythmias. Circulation. 1980;62(5):996–1010.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 113.
    Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ, et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2016;67(13):e27–e115.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 114.
    Alabed S, Sabouni A, Providencia R, Atallah E, Qintar M, Chico TJ. Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia. Cochrane Database Syst Rev. 2017;10:Cd005154.PubMedPubMedCentralGoogle Scholar
  79. 115.
    Delaney B, Loy J, Kelly AM. The relative efficacy of adenosine versus verapamil for the treatment of stable paroxysmal supraventricular tachycardia in adults: a meta-analysis. Eur J Emerg Med. 2011;18(3):148–52.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 116.
    Rosei EA, Dal Palu C, Leonetti G, Magnani B, Pessina A, Zanchetti A. Clinical results of the verapamil in hypertension and atherosclerosis study. VHAS investigators. J Hypertens. 1997;15(11):1337–44.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 117.
    Zanchetti A, Rosei EA, Dal Palu C, Leonetti G, Magnani B, Pessina A. The verapamil in hypertension and atherosclerosis study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens. 1998;16(11):1667–76.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 118.
    Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, Neaton JD, et al. Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region. J Hypertens. 2005;23(5):1099–106.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 119.
    Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The international verapamil-Trandolapril study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805–16.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 120.
    Lee TH, Salomon DR, Rayment CM, Antman EM. Hypotension and sinus arrest with exercise-induced hyperkalemia and combined verapamil/propranolol therapy. Am J Med. 1986;80(6):1203–4.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 121.
    Joyal M, Cremer KF, Pieper JA, Feldman RL, Pepine CJ. Systemic, left ventricular and coronary hemodynamic effects of intravenous diltiazem in coronary artery disease. Am J Cardiol. 1985;56(7):413–7.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 122.
    Kenny J, Daly K, Bergman G, Kerkez S, Jewitt DE. Beneficial effects of diltiazem in coronary artery disease. Br Heart J. 1984;52(1):53–6.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 123.
    Tsuneda T, Yamashita T, Fukunami M, Kumagai K, Niwano S, Okumura K, et al. Rate control and quality of life in patients with permanent atrial fibrillation: the quality of life and atrial fibrillation (QOLAF) study. Circ J. 2006;70(8):965–70.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 124.
    Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The adverse experience committee; and the multicenter diltiazem postinfarction research group. Circulation. 1991;83(1):52–60.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 125.
    Sugimoto T, Ishikawa T, Kaseno K, Nakase S. Electrophysiologic effects of diltiazem, a calcium antagonist, in patients with impaired sinus or atrioventricular node function. Angiology. 1980;31(10):700–9.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 126.
    Zeltser D, Justo D, Halkin A, Rosso R, Ish-Shalom M, Hochenberg M, et al. Drug-induced atrioventricular block: prognosis after discontinuation of the culprit drug. J Am Coll Cardiol. 2004;44(1):105–8.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 127.
    Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic diltiazem (NORDIL) study. Lancet. 2000;356(9227):359–65.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Alexandra-Maria Neagoe
    • 1
  • Emrush Rexhaj
    • 1
    • 2
  • Ehud Grossman
    • 3
  • Franz H. Messerli
    • 4
  1. 1.Department of CardiologyUniversity Hospital BernBernSwitzerland
  2. 2.Department for Biomedical ResearchUniversity of BernBernSwitzerland
  3. 3.The Chaim Sheba Medical Center, The Sackler Faculty of MedicineTel-Aviv UniversityTel AvivIsrael
  4. 4.Department of CardiologyUniversity of BernBernSwitzerland

Personalised recommendations